Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Trading Up 0.1 %

Organovo stock opened at $0.49 on Monday. Organovo has a 1-year low of $0.32 and a 1-year high of $1.74. The company has a market cap of $7.49 million, a P/E ratio of -0.46 and a beta of 0.56. The company has a fifty day simple moving average of $0.41 and a 200 day simple moving average of $0.51.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Organovo stock. Armistice Capital LLC purchased a new stake in Organovo Holdings, Inc. (NASDAQ:ONVO) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 929,000 shares of the medical research company’s stock, valued at approximately $708,000. Armistice Capital LLC owned 6.46% of Organovo as of its most recent SEC filing. Institutional investors own 8.23% of the company’s stock.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.